These preclinical observations provided a rationale for combining anti-HER2 agents trastuzumab and lapatinib with bevacizumab in patients with metastatic HER2-positive breast cancer pretreated with a median of 7 regimens, including HER2-targeted therapies. Here, ERBB2 is linked to breast carcinoma.